Drugs / FEMJA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03949881 | Nov 2020 → May 2031 expected | limbal stem cell deficiency | Hospices Civils de Lyon | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FEMJA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03949881 ↗ |
| Action | Restore | “A new way to treat these patients is to cultivate autologous corneal-like epithelium, and to graft it in order to restore transparency.” NCT03949881 ↗ |
| Modality | Cell therapy | “The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma.” NCT03949881 ↗ |
| Route | Other | “The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma.” NCT03949881 ↗ |